Replies to post #7256 on Halozyme Therapeutics Inc (HALO)

[maumar]

I guess that is what they come up with on a DCF basis but who knows why they bother with tiny changes to their PTs. The other odd thing is that they raised their FY22E EPS estimate from 2.15 to 2.25 and lowered their FY23E estimate from 3.13 to 2.87, which are slightly higher than the current high estimate (2.2) for 2022 and lower than the low estimate (2.91) for 2023 on yahoo.finance. So they are overweight but less bullish than all the other analysts for 2023 on the day we find out Halo will most likely have another Enhanze product in March 2023.

I am concerned that even if the stock breaks out, large firms like JPM or MS may downgrade the stock if they don't raise their PTs.